BeOne Medicines Ltd. (ONC)
NASDAQ: ONC · Real-Time Price · USD
307.51
+19.41 (6.74%)
Aug 13, 2025, 4:00 PM - Market closed
BeOne Medicines Stock Forecast
Stock Price Forecast
According to 9 professional analysts, the 12-month price target for BeOne Medicines stock ranges from a low of $311 to a high of $365. The average analyst price target of $335.78 forecasts a 9.19% increase in the stock price over the next year.
Price Target: $335.78 (+9.19%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for BeOne Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 5 | 5 | 7 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 7 | 7 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $349 → $364 | Buy | Maintains | $349 → $364 | +18.37% | Aug 7, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $350 → $365 | Strong Buy | Maintains | $350 → $365 | +18.70% | Aug 7, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $321 → $345 | Buy | Maintains | $321 → $345 | +12.19% | Jul 17, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $311 → $349 | Buy | Maintains | $311 → $349 | +13.49% | Jul 16, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $313 → $330 | Buy | Maintains | $313 → $330 | +7.31% | Jun 27, 2025 |
Financial Forecast
Revenue This Year
36.78B
from 3.81B
Increased by 865.19%
Revenue Next Year
44.54B
from 36.78B
Increased by 21.12%
EPS This Year
0.35
from -6.12
EPS Next Year
2.58
from 0.35
Increased by 641.69%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 39.2B | 48.9B | 56.0B | ||
| Avg | 36.8B | 44.5B | 51.3B | ||
| Low | 35.1B | 41.4B | 46.0B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 929.8% | 33.1% | 25.8% | ||
| Avg | 865.2% | 21.1% | 15.3% | ||
| Low | 822.3% | 12.5% | 3.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.91 | 3.69 | 5.71 | ||
| Avg | 0.35 | 2.58 | 5.24 | ||
| Low | 0.10 | 1.57 | 4.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 960.5% | 121.3% | ||
| Avg | - | 641.7% | 103.3% | ||
| Low | - | 351.0% | 83.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.